vs
LEE ENTERPRISES, Inc（LEE）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
LEE ENTERPRISES, Inc的季度营收约是MESA LABORATORIES INC的2.0倍（$130.1M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -4.3%，领先9.9%），MESA LABORATORIES INC同比增速更快（3.6% vs -10.0%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $3.7M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -5.8%）
李企业是一家上市美国传媒企业，在全美25个州运营着72份日报，同时还经营超过350份周报、分类广告刊物及各类专业刊物。公司由阿尔弗雷德·威尔逊·李于1890年创立，总部坐落于爱荷华州达文波特。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
LEE vs MLAB — 直观对比
营收规模更大
LEE
是对方的2.0倍
$65.1M
营收增速更快
MLAB
高出13.7%
-10.0%
净利率更高
MLAB
高出9.9%
-4.3%
自由现金流更多
MLAB
多$14.3M
$3.7M
两年增速更快
MLAB
近两年复合增速
-5.8%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $130.1M | $65.1M |
| 净利润 | $-5.6M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 4.0% | 12.2% |
| 净利率 | -4.3% | 5.6% |
| 营收同比 | -10.0% | 3.6% |
| 净利润同比 | 66.5% | 316.6% |
| 每股收益（稀释后） | $-0.92 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LEEMLAB
| Q4 25 | $130.1M | $65.1M | ||
| Q3 25 | $139.1M | $60.7M | ||
| Q2 25 | $141.3M | $59.5M | ||
| Q1 25 | $137.4M | $62.1M | ||
| Q4 24 | $144.6M | $62.8M | ||
| Q3 24 | $158.6M | $57.8M | ||
| Q2 24 | $150.6M | $58.2M | ||
| Q1 24 | $146.6M | $58.9M |
净利润LEEMLAB
| Q4 25 | $-5.6M | $3.6M | ||
| Q3 25 | $-6.4M | $2.5M | ||
| Q2 25 | $-1.9M | $4.7M | ||
| Q1 25 | $-12.5M | $-7.1M | ||
| Q4 24 | $-16.7M | $-1.7M | ||
| Q3 24 | $-10.1M | $3.4M | ||
| Q2 24 | $-4.3M | $3.4M | ||
| Q1 24 | $-12.2M | $-254.6M |
毛利率LEEMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率LEEMLAB
| Q4 25 | 4.0% | 12.2% | ||
| Q3 25 | -1.0% | 7.8% | ||
| Q2 25 | 3.3% | 5.1% | ||
| Q1 25 | -3.3% | 2.4% | ||
| Q4 24 | -2.3% | 9.2% | ||
| Q3 24 | -2.3% | 6.1% | ||
| Q2 24 | 3.3% | 9.6% | ||
| Q1 24 | -3.1% | -460.6% |
净利率LEEMLAB
| Q4 25 | -4.3% | 5.6% | ||
| Q3 25 | -4.6% | 4.1% | ||
| Q2 25 | -1.4% | 8.0% | ||
| Q1 25 | -9.1% | -11.4% | ||
| Q4 24 | -11.6% | -2.7% | ||
| Q3 24 | -6.4% | 5.9% | ||
| Q2 24 | -2.8% | 5.8% | ||
| Q1 24 | -8.3% | -432.2% |
每股收益（稀释后）LEEMLAB
| Q4 25 | $-0.92 | $0.65 | ||
| Q3 25 | $-1.02 | $0.45 | ||
| Q2 25 | $-0.31 | $0.85 | ||
| Q1 25 | $-2.07 | $-1.30 | ||
| Q4 24 | $-2.80 | $-0.31 | ||
| Q3 24 | $-1.68 | $0.63 | ||
| Q2 24 | $-0.73 | $0.62 | ||
| Q1 24 | $-2.06 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.6M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $-48.7M | $186.7M |
| 总资产 | $592.6M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资LEEMLAB
| Q4 25 | $12.6M | $29.0M | ||
| Q3 25 | $10.0M | $20.4M | ||
| Q2 25 | $14.1M | $21.3M | ||
| Q1 25 | $4.7M | $27.3M | ||
| Q4 24 | $6.1M | $27.3M | ||
| Q3 24 | $9.6M | $24.3M | ||
| Q2 24 | $13.4M | $28.5M | ||
| Q1 24 | $16.1M | $28.2M |
总债务LEEMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益LEEMLAB
| Q4 25 | $-48.7M | $186.7M | ||
| Q3 25 | $-43.3M | $178.5M | ||
| Q2 25 | $-40.5M | $172.5M | ||
| Q1 25 | $-38.9M | $159.8M | ||
| Q4 24 | $-26.7M | $155.2M | ||
| Q3 24 | $-9.9M | $161.5M | ||
| Q2 24 | $4.0M | $150.7M | ||
| Q1 24 | $7.9M | $145.4M |
总资产LEEMLAB
| Q4 25 | $592.6M | $434.8M | ||
| Q3 25 | $601.7M | $430.4M | ||
| Q2 25 | $622.7M | $435.7M | ||
| Q1 25 | $623.9M | $433.3M | ||
| Q4 24 | $633.0M | $433.3M | ||
| Q3 24 | $649.2M | $454.1M | ||
| Q2 24 | $677.5M | $440.4M | ||
| Q1 24 | $684.8M | $446.8M |
负债/权益比LEEMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.5M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $3.7M | $18.0M |
| 自由现金流率自由现金流/营收 | 2.9% | 27.7% |
| 资本支出强度资本支出/营收 | 0.6% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $1.5M | $37.9M |
8季度趋势，按日历期对齐
经营现金流LEEMLAB
| Q4 25 | $4.5M | $18.8M | ||
| Q3 25 | $-6.3M | $8.2M | ||
| Q2 25 | $8.9M | $1.9M | ||
| Q1 25 | $-790.0K | $12.7M | ||
| Q4 24 | $-7.3M | $18.1M | ||
| Q3 24 | $-261.0K | $5.3M | ||
| Q2 24 | $-1.9M | $10.7M | ||
| Q1 24 | $3.2M | $12.9M |
自由现金流LEEMLAB
| Q4 25 | $3.7M | $18.0M | ||
| Q3 25 | $-8.3M | $7.1M | ||
| Q2 25 | $8.3M | $884.0K | ||
| Q1 25 | $-2.2M | $11.9M | ||
| Q4 24 | $-8.9M | $17.3M | ||
| Q3 24 | $-2.9M | $3.5M | ||
| Q2 24 | $-5.5M | $9.9M | ||
| Q1 24 | $1.3M | $12.3M |
自由现金流率LEEMLAB
| Q4 25 | 2.9% | 27.7% | ||
| Q3 25 | -6.0% | 11.7% | ||
| Q2 25 | 5.9% | 1.5% | ||
| Q1 25 | -1.6% | 19.2% | ||
| Q4 24 | -6.1% | 27.6% | ||
| Q3 24 | -1.8% | 6.0% | ||
| Q2 24 | -3.6% | 16.9% | ||
| Q1 24 | 0.9% | 21.0% |
资本支出强度LEEMLAB
| Q4 25 | 0.6% | 1.1% | ||
| Q3 25 | 1.4% | 1.8% | ||
| Q2 25 | 0.4% | 1.7% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 1.1% | 1.3% | ||
| Q3 24 | 1.7% | 3.1% | ||
| Q2 24 | 2.4% | 1.5% | ||
| Q1 24 | 1.3% | 0.9% |
现金转化率LEEMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LEE
| Advertising And Marketing Services | $60.0M | 46% |
| Subscription And Circulation | $57.7M | 44% |
| Other | $12.4M | 10% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
